cycle arrest at G 0 /G 1 stage and decreased the protein level of cyclin E/cyclin-dependent kinases (cdk) 2 and/or cyclin D/ cdk4/cdk6. Conclusion: These results suggest the inhibitory effect of IF1 knockdown on BCa cell proliferation is via the suppression of cyclins and cdks related to G 1 /S transition and then induction of G 0 /G 1 arrest, and firstly indicate IF1 mediates the tumor cell cycle. We concluded that IF1 may be a novel therapeutic target for BCa.
Introduction
The endogenous F 1 F o -ATPase inhibitory factor 1 (IF1) is a naturally occurring protein in mammals and predominantly located inside the mitochondrial matrix [1] . When mitochondrial respiratory activity is impaired or a cell is deprived of oxygen, IF1 becomes active as a dimer and then binds to the β -subunit of F 1 F o -ATPase ( β F 1 ), and finally acts to block the ATP-hydrolyzing activity of the F 1 F o -ATPase [2] . Although the physiological role of IF1 has been clarified several decades ago, it is now regarded as a pleiotropic factor exerting diverse cellular effects [3] [4] [5] , and many of them are potentially related to tumorigenesis, including cell proliferation, migration, invasion and angiogenesis [6, 7] .
Some studies show that IF1 is upregulated in various common human cancers, and increased expression of IF1 in hepatocellular carcinoma predicts poor survival and disease recurrence after surgery [7] [8] [9] . But other reports claim that a low tumor expression of IF1 predicts the worst prognosis overall for breast and colon cancer patients [10] . These results suggest that the functional effect of IF1 in human tumors is complicated. Thus, more mechanistic studies are required to elucidate the role of IF1 in human carcinomas.
Dysregulation of cellular proliferation is a hallmark of cancer [11] . Cell proliferation relies on the activation of cyclins, which in turn bind to cyclin-dependent kinases (cdks), forming complexes that drive progression through the different phases of the cell cycle and ultimately lead to cell growth [12] . This is coupled to regulatory mechanisms by cdk inhibitors that allow or prevent cells to progress through the cell cycle. Although previous studies suggest IF1 mediates tumor cell activities, such as cell proliferation, invasion and response to toxic agents [6, 7, 13] , it still remains unclear whether IF1 is linked to cell cycle progression. In this study, we investigated the potential role of IF1 on cell cycle progression using human bladder cancer (BCa) cells in order to reveal new mechanisms of IF1-mediated tumor progression.
Materials and Methods

Tissue Samples, Histology and Immunohistochemistry
We obtained BCa specimens (n = 15) from patients undergoing transurethral resection or radical cystectomy at the Kochi Medical University Hospital ( table 1 ). The current research was approved by the Ethical Committee of the Kochi Medical School (No. 26). Frozen tissues were cut into 10-μm-thick sections. Slides were then stained with hematoxylin and eosin to distinguish normal from tumor tissue. IF1 expression was detected by immunohistochemistry. The tissue sections were deparaffinized in Lemosol ® A, rehydrated in graded ethanol series and transferred to phosphatebuffered saline (PBS). Endogenous peroxidases were blocked by incubation in 0.3% hydrogen peroxide in PBS for 30 min at room temperature. The samples were washed three times with PBS and then treated with citric acid buffer (pH 6.0) under microwave heating. The samples were incubated overnight at 4 ° C with the appropriate dilution (1: 100) of monoclonal IF1 antibody (Santa Cruz Biotechnology Inc.). They were then rinsed three times with PBS and incubated for 15 min with biotinylated link antibody and streptavidin-HRP (DakoCytomation Co. Ltd., Kyoto, Japan). The slides were rinsed with PBS and incubated for 5 min with diaminobenzidine. The sections were washed three times with PBS and counterstained with hematoxylin.
Cell Lines, Culture Conditions and Transfection
All human BCa cells except T24 cells were grown as monolayers in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). T24 cells were cultured in F12 medium supplemented with 10% FBS. Human bladder epithelial cells from the apex region (HBEC-A) and dome region (HBEC-D) were purchased from Kurabo Industries Ltd. and maintained in UroLife TM A basal medium and LifeFactors, and UroLife TM D complete medium (Lifeline Cell Technology, Frederick, Md., USA), respectively. These cells were incubated at 37 ° C in a 5% CO 2 environment. Small interfering RNA (siRNA; Qiagen S100908075) was used to suppress the expression of IF1, and transfection was carried out using HiPerFect transfection reagent according to the manufacturer's fast-forward protocol. One milliliter medium contains 5 μl HiPerFect transfection reagent and 5 pmol IF1 or control siRNA.
Cell Proliferation and Colony-Forming Assay
Cell proliferation was determined by 3-(4, 5-dimethyl-thiogol-2-yl)-2, 5-diplenyltetrazolium (MTT) assay, as we previously reported [14] . Colony formation was assessed as described [15] . Briefly, cells transfected with IF1 siRNA (SiIF1) or control siRNA (SiCL) were plated in six-well plates at a density of 300 cells/well. Plates were incubated for 10 days, and colonies were fixed in 70% ethanol and stained with crystal violet.
Cell Migration Assay
Cell migration was determined using the wound healing assay, as described previously [16] . Briefly, cells transfected with SiIF1 or SiCL were plated in 24-well plates at a density of 5,000 cells/well. After incubation for 24 h, wound injury was made with the tip of a sterile micropipette, and the detached cells were removed by washing with fresh medium. Cells were then incubated and allowed to migrate for another 24 h. Photographs were taken and the migration index was calculated as follows: migration index = [(initial wound width -width of the wound at the time point tested)/ initial wound width] × 100%.
Flow-Cytometric Analysis
After transfection, cells were trypsinized and washed with PBS. Cells were then stained with the bromodeoxyuridine (BrdU) flow kit (BD Biosciences) to determine the cell cycle according to the (100) manufacturer's protocol. Annexin V and propidium iodide (PI) dyes were used to detect apoptosis. Cells were stained with 100 n M tetramethylrhodamine methyl ester (TMRM) and 5 μ M MitoSOX for 15 min to determine mitochondrial membrane potential (ΔΨ m ) and reactive oxygen species (ROS), respectively. The stained cells were processed for LSRFortessa or FACScan (BD Biosciences). A minimum 10,000 cells per sample were collected and subsequently analyzed with FlowJo software.
Western Blot
Cells were harvested and then lysed by lysis buffer with protease inhibitor cocktail. Proteins from the cell lysate were performed on SDS-PAGE and transferred onto polyvinylidene difluoride membranes. After blocking, the membranes were probed with the appropriate antibodies against IF1, β F 1 (Abcam plc., Cambridge, UK), cyclin D3 (DSC-22), cyclin E (HE12), cyclin-dependent kinase (cdk) 2 (D-12), cdk4 (DCS-156), cdk6 (DSC-83) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Abcam), and then detected by enhanced chemiluminescence assay (Pierce Biotechnology, Rockford, Ill., USA). All other antibodies were purchased from Santa Cruz Biotechnology Inc.
Statistics
Data are expressed as means and SD. Student's independent two-sample t test was used for comparisons. A value of p < 0.05 was considered statistically significant.
Results
IF1 Expression Is Upregulated in Human BCa
We firstly examined the expression of IF1 in 15 BCa tissue samples and 12 corresponding adjacent noncancerous bladder tissues of them by immunostaining using IF1 antibody. Immunohistochemistry ( fig. 1 a) demonstrated that the expression of IF1 was negligible in normal bladder epithelial cells, but significantly increased in BCa tissue samples. The relative expression of IF1 in BCa cell lines indicated a very large variability by Western blot (data not shown), but was upregulated compared to the normal bladder cell lines ( fig. 1 b) . The resulting data showed overexpression of IF1 in BCa tissues and cells compared to the normal bladder tissues and cells.
Knockdown of IF1 Expression Induces Cell Growth and Migration Inhibition in BCa Cells
Given the increased expression of IF1 in BCa tissues and cell lines, we then determined whether IF1 inhibition affected BCa cell growth in vitro using T24 and UM-UC-3 cells, which have relatively high proliferative and invasion abilities. Cells were transfected with SiCL or SiIF1, and SiIF1 transfection successfully reduced the expression of IF1 protein ( fig. 2 a) . Knockdown of IF1 resulted in a decreased number of BCa colonies compared with SiCL transfection ( fig. 2 b) . In addition, IF1 knockdown cells showed decreased cell viability. Cell viability was reduced by 7, 27 and 25% in T24 cells, and 14, 9 and 20% in UM-UC-3 cells after transfection for 24, 48 and 72 h, respectively ( fig. 2 c, d ). Taken together, these results indicated silencing of IF1 suppressed BCa cell growth.
Elevated migration heightens the metastatic potential of cancer cells. This may be independent of cell-proliferative rates. Therefore, we investigated the effect of IF1 knockdown on BCa cell migration determined by a wound healing assay. As shown in figure 3 a, the knockdown of IF1 inhibited the migration of T24. A similar result was also found in UM-UC-3 cells ( fig. 3 b) . The migration index of SiIF1 cells was 29% compared to 52% in SiCL cells in T24 cells. In UM-UC-3 cells, the migration index of SiIF1 cells was reduced by 17% (from 49% to 32%; fig. 3 c) . These data suggested that silencing of IF1 also suppressed the cell migration in BCa cells.
Knockdown of IF1 Expression Induces G 0 /G 1 Cell Cycle Arrest in BCa Cells
To examine the mechanism by which IF1 inhibition may affect cell growth, cells were transfected with SiIF1 or SiCL, and cell cycle analysis was then carried out. After BrdU staining, flow-cytometric analysis revealed knockdown of IF1 significantly decreased the S-phase popula- 228 tion from 28.9 to 8.6% and increased G 0 /G 1 fraction from 54.3 to 72.6%, indicating a G 0 /G 1 cell cycle arrest in T24 cells ( fig. 4 a, b) . A similar result was also found in UM-UC-3 cells. IF1 knockdown decreased the percentage of UM-UC-3 cells in S phase by nearly 21% and increased G 0 /G 1 population from 48.9 to 72.0% ( fig. 4 c, d ). In addition, there was no significant increase in apoptosis upon IF1 knockdown in T24 and UM-UC-3 cells detected by BrdU/7-AAD and annexin V/PI staining (data not shown). Taken together, these results suggested silencing of IF1 by siRNA was associated with a block in cell cycle progression and not increased apoptosis in BCa cells.
To elucidate the molecular changes associated with the observed G 0 /G 1 cell cycle arrest, we determined the expression of a panel of key regulatory proteins of the cell cycle machinery by Western blot analysis ( fig. 4 e) . Inhibition of IF1 in T24 and UM-UC-3 cells resulted in the suppression of G 1 /S transition molecules cyclin E, cdk2, cdk4 and cdk6. In addition, IF1 knockdown also decreased the protein level of cyclin D and increased the expression of cdk inhibitor p21 in UM-UC-3 cells. However, converse results that silencing of IF1 increased cyclin D expression and decreased p21 expression were found in T24 cells. Thus, our data suggested that the inhibition of IF1 prevents urothelial cancer cell cycle progression from G 1 to S phase at least through the regulation of key cell cycle factors ( fig. 4 f) .
Knockdown of IF1 Expression Increases Mitochondrial ROS in BCa Cells
As mitochondria play a critical role in cell fate and IF1 could regulate mitochondrial function [17] , we next analyzed the effect of IF1 knockdown on mitochondrial ΔΨ m and ROS. Consistent with the previous report by Formentini et al. [6] , SiIF1-mediated silencing of IF1 exhibited a marginal effect on mitochondrial ΔΨ m ( fig. 5 a, b) . However, after MitoSOX staining, flow-cytometric analysis showed enhanced fluorescence intensity in SiIF1 cells compared to SiCL cells in T24 and UM-UC-3 cells ( fig. 5 c,  d ), indicating IF1 knockdown led to an increase in mitochondrial ROS of BCa cells.
Discussion
IF1 is a highly conserved protein encoded in the nuclear ATPIF1 gene. It has unique capacity to inhibit the hydrolase activity of F 1 F o -ATP synthase, which is its reverse role. IF1 is known to play a major role in heme biosynthesis and mitochondrial respiratory chain dysfunction [3, 18] , and, moreover, has been linked to different cancer types [8-10, 19, 20] . Although IF1 has been associated with tumor activity [3, 6, 7] , IF1 has not been associated with specific changes in the cell cycle previously. In the current study, we found that targeting IF1 reduced the expression of cell cycle progression regulatory factors and then induced cell cycle arrest, and finally inhibited BCa cell proliferation. This is the first report to show IF1 expression might play a critical role in cell cycle progression. Aberrations in cell cycle progression occur in the majority of human malignancies [16] . The cell cycle is a highly controlled process that involves tight regulation of key molecules that allow cells to progress between phases of the cell cycle. Different combinations of cyclin and cdk subunits operate at checkpoints to integrate mitogenic and antiproliferative signals. Among them, cyclins D and E play a critical role in controlling G 1 /S transition, which are often abnormally expressed in human tumors. The present study indicates that silencing of IF1 in carcinoma cells downregulated the expression of cyclin E/cdk2, which can lead to the phosphorylation of downstream targets for growth progression in T24 and UM-UC-3 cells, and decreased the levels of cyclin D/cdk4/cdk6 known as protooncogenic factors of the G 1 /S phase checkpoint in UM-UC-3 cells. But, unexpectedly, we found that cyclin D expression was increased after silencing of IF1 in T24 cells. Kang et al. [21] demonstrated that al- though cyclin D levels increased, the downregulation of cdk4 might result in the decrease of the cyclin D/cdk4 complex. Likewise, the decrease in cdk4 and cdk6 might result in the downregulation of the cyclin D/cdk4/cdk6 complex even though cyclin D levels were increased in T24 cells. Therefore, G 0 /G 1 arrest associated IF1 knockdown in T24 cells originates from the only downregulation of the cyclin E/cdk2 complex. As a result, the downregulation of the cyclin E/cdk2 probably induces the downregulation of the cyclin D/cdk4/cdk6 complex. The p21 protein is the first identified cdk inhibitor and plays a critical role in cell cycle progression [22] . It effectively inhibits cdk2, cdk4 and cdk6 by blocking kinase activity or interfering with activating phosphorylation, which have a direct function in G 1 /S transition [23] . Increases in p21 levels were associated with decreased cdk levels in UM-UC-3 cells. In contrast, the downregulation of cdk levels in T24 cells was not associated with the role of p21 since IF1 knockdown resulted in suppressed levels. These data suggest that the control of cell cycle regulatory factors by IF1 may be cell-type specific, and other factors (p27, INK family and ERK) [23, 24] , besides p21, may be involved in IF1 inhibition-mediated regulation of cell cycle regulatory factors.
In our study, we showed that IF1 knockdown delayed cell cycle progression through the G 1 phase of the cell cycle signifying cell arrest at the G 0 /G 1 phase. Combined with our observation that depletion of IF1 leads to decreased cell viability and colony formation of BCa cells, which is not due to an increase in cell death but might be related to cell proliferation, we can conclude that knockdown of IF1 induces tumor cell growth inhibition, at least in part by causing G 0 /G 1 -phase cell cycle arrest via the downregulation of the cyclin E/cdk2 and/or cyclin D/ cdk4/cdk6 complexes ( fig. 4 f) . As high overexpression of IF1 is found in various tumor types, the results also suggest that IF1 may be an oncogene and confer its protooncogenic properties by causing cell progression through G 1 /S transition via the upregulation of the cyclin E/cdk2 and/or cyclin D/cdk4/cdk6 complexes.
Overexpression of IF1 has been observed in some tumors types (e.g. breast and lung cancers) and has been associated with their prognosis, but no attention has been given to IF1 in human BCa. In our study, IF1 expression was noted to be increased in BCa tissues and cells compared with normal bladder tissues and cells. Importantly, knockdown of IF1 inhibited BCa cell growth via cell cycle arrest at the G 0 /G 1 phase, which may be an opportunity to effectively treat BCa as well as delay its progression, and thus be of benefit to the patients.
As IF1 is predominantly located inside the mitochondrial matrix and possibly regulates mitochondrial function, we then studied the potential effect of IF1 on mitochondrial ROS. We found here that IF1 knockdown increased mitochondrial ROS, which was confirmed using MitoSOX and consistent with a previous study [4] . Increased ROS generation may originate from a reduced level of the NADH:NAD+ ratio [4] , but not from the change in ΔΨ m since knockdown of IF1 has no effect. Although the role of increased ROS levels by IF1 inhibition was not studied here, combined with the results of previous studies and the critical role of ROS in cell proliferation, cell cycle arrest and cell survival, it is not difficult to point out that IF1 could regulate tumor cell fate through ROS in human carcinomas. It has been demonstrated that loss of ΔΨ m triggers a Ca 2+ -mediated cascade that leads to apoptosis. The lack of a change in ΔΨ m and the absence of apoptosis induction by IF1 knockdown in our study confirm that the decrease in cell growth seen in IF1 knockdown cells is related to cell proliferation.
Based on in vitro experiments, we and other researchers showed that silencing of IF1 decreased tumor cell proliferation, while Fujikawa et al. [25] indicated that depletion of IF1 did not hamper cell growth. They suggested that the functional role of IF1 in human carcinomas may differ in cancer cells and tumor types. Although IF1 has been shown to mediate cell cycle progression in this study, it is largely unclear how IF1 activates cell cycle progression regulatory factors. We will focus on the mechanisms of IF1-mediated tumor activity and IF1-mediated cell cycle progression in detail in future studies. Considering that the clinical relevance of IF1 in human tumors is controversial and the few cases examined in our study, the clinical association between IF1 and BCa should also be further scrutinized in a larger number of samples.
Taken together, the results presented here show the importance of IF1 in human BCa as it is related to tumor cell cycle progression. We are the first to show that cell cycle arrest associated with the downregulation of IF1 was accompanied by the depletion of G 1 cell cycle transition in parallel with the downregulation of key cell cycle regulators. With the ability to identify subsets of cancer patients with IF1 overexpression, antagonism of this target may provide a useful therapeutic strategy for BCa and other tumors.
